

6 May 2024

ASX Announcement

Notice of Change in Auditor

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) advises that in accordance with Listing Rule 3.16.3, BDO Audit Pty Ltd (BDO Audit) has been appointed as auditor of the Company. The appointment follows the resignation of BDO Audit (WA) Pty Ltd (BDO WA) and ASIC's consent to the resignation in accordance with s329(5) of the Corporations Act 2001 (the Act).

In accordance with ASIC Regulatory Guide 26, paragraphs RG 26.59-RG 26.61, the Company provides the following information:

The outgoing auditor is: BDO Audit (WA) Pty Ltd
Level 9, Mia Yellagonga Tower 2, 5 Spring St, Perth WA 6000

The incoming auditor is: BDO Audit Pty Ltd
Level 9, Mia Yellagonga Tower 2, 5 Spring St, Perth WA 6000

The change of auditor arose as a result of BDO WA restructuring its audit practice whereby audits will be conducted by BDO Audit, an authorised audit company, rather than BDO WA.

In accordance with s327C of the Act, a resolution will be proposed at the Company's next Annual General Meeting to confirm the appointment of the Company's auditor.

This announcement was authorised for release by the Board of Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator focused on developing and commercialising novel formulations and uses of povidone-iodine (www.firebrickpharma.com). The Company has successfully developed a povidone-iodine nasal spray (Nasodine®) and filed international trademarks and multiple patents on the product, including pharmaceutical formulation and use patents. The Company has also completed six clinical trials for the nasal spray, which have affirmed the product's safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings. Firebrick is now commercialising its innovative nasal spray as a product to kill the germs that can cause nasal infections, with Singapore being the first market to launch the product.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com